Results 11 to 20 of about 119,295 (311)

Evaluation of mutations in KRAS and BRAF genes in Iranian population with diffuse gastric cancer [PDF]

World Cancer Research Journal, 2019
OBJECTIVE: RAS proteins control signaling pathways which are the main regulators of the normal cell growth and malignant transformation cells. The point mutations in the KRAS gene are current event in numerous human cancers including pancreatic, lung ...
M. Saneipour, A. Moridnia
doaj   +3 more sources

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma [PDF]

Case Reports in Oncology, 2019
Approximately 50% of patients with metastatic melanoma harbor an activating BRAF mutation. Tumors with activating mutation <i>BRAF</i> gene proliferate excessively and can be treated with targeted BRAF-inhibitors in combination with MEK inhibitors. The most common BRAF mutation occurs at amino acid position 600. Other <i>BRAF</i>
Sara Bjursten, Christoffer Vannas, Stefan Filges, Florian Puls, Ankur Pandita, Henrik Fagman, Anders Ståhlberg, Max Levin   +7 more
openaire   +4 more sources

BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review

Journal of Clinical Medicine, 2023
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths globally. BRAF mutation is present in about 10% of CRC patients and is associated with a poor response to chemotherapy. These patients have a relatively poor prognosis. This review aims to assess the efficacy and safety of BRAF inhibitors in BRAF-mutated CRC patients.
Wajeeha Aiman, Muhammad Ashar Ali, Samer Jumean, Ummul Asfeen, Jose Garcia, Murad Quirem, Amaar Ahmad, Mohammad Nabil Rayad, Osama Alkhlaifat, Bader Al Omour, Venkata S. Chemarthi, Michael Maroules, Gunwant Guron, Hamid Shaaban   +13 more
openaire   +3 more sources

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

Oncotarget, 2014
Almost 50% of metastatic melanoma patients harbor a BRAF(V600) mutation and the introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. However, most patients develop
SPAGNOLO, FRANCESCO, GHIORZO, PAOLA, Queirolo, P.   +2 more
openaire   +4 more sources

Improving the Accuracy of Papillary Thyroid Cancer Pathological Evaluation With Digital PCR Detection of the BRAF V600E Mutation. [PDF]

J Clin Lab Anal
This study developed a highly sensitive and specific digital PCR assay for BRAF V600E mutation detection in papillary thyroid cancer (PTC). The increased sensitivity of BRAF mutation detection directly led to more accurate pathological diagnosis of PTC and in turn improved clinical care in patients with limited sample availability or in samples with ...
Yu N, Zhang K, Jiang Y, Zheng L, He X, He Q, Dai M, Hu T, Tang D, Jin J, Huang X, Xiao L.   +11 more
europepmc   +2 more sources

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]

, 2014
BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Ferguson, J., Claudia Wellbrock, Erice, O., Margison, G.P., Goicoechea, I., Geoffrey P Margison, Margison, Geoffrey P, Wellbrock, C., Wellbrock, Claudia, Jennnifer Ferguson, Arozarena, Imanol, Goicoechea, Ibai, Imanol Arozarena, Ferguson, Jennnifer, Erice, Oihane, Oihane Erice, Ibai Goicoechea   +16 more
core   +1 more source

BRAF in the cross-hairs [PDF]

Expert Review of Hematology, 2019
Hairy cell leukemia (HCL) is a rare, chronic B-cell lymphoproliferative disorder characterized by distinctive morphologic features and an indolent clinical course. The discovery of a recurrent activating mutation in BRAF (BRAF V600E) as a disease-defining genetic event in HCL has substantial diagnostic and therapeutic implications.
Mark B. Geyer, Omar Abdel-Wahab, Martin S. Tallman   +2 more
openaire   +2 more sources

BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status [PDF]

, 2006
BACKGROUND: BRAF is a member of RAF family of serine/threonine kinases and mediates cellular responses to growth signals through the RAS-RAF-MAP kinase pathway.
Kazuyuki Kawakami, Andrew Ruszkiewicz, Kawakami, K., Ruszkiewicz, A., Bennet, G., Li, W., Iacopetta, B., James Moore, Wei Qi Li, Barry Iacopetta, Moore, J., Graeme Bennett   +11 more
core   +1 more source

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models [PDF]

, 2018
Background: Mounting evidence suggests that RAF-mediated MEK activation plays a crucial role in paradox MAPK (re)activation, leading to resistance and therapeutic failure with agents hitting a single step along the MAPK cascade.
Francesco Cognetti, Del Curatolo, Anais, Falcone, Italia, Fabiana Conciatori, Sette,Giovann i, Milella, Michele, Marabese, Mirko, Ciuffreda, Ludovica, Sabrina D’Agosto, De Maria Marchiano, Ruggero, Conciatori, Fabiana, De Maria, Ruggero, Scarpa, Aldo, Massimo Broggini, Sette, Giovanni, Del Bufalo, Donatella, Giovanni Sette, Senji Shirasawa, Teresa De Luca, D’Agosto, Sabrina, Shirasawa, Senji, Isabella Sperduti, Chiara Bazzichetto, Anais Del Curatolo, Aldo Scarpa, Ruggero De Maria, Ludovica Ciuffreda, D'Agosto, Sabrina, Donatella Del Bufalo, Broggini, Massimo, Cognetti, Francesco, Vincenzo Corbo, Sperduti, Isabella, Ursula Cesta Incani, Mirko Marabese, Eramo, Adriana, De Luca, Teresa, Italia Falcone, Bazzichetto, Chiara, Cesta Incani, Ursula, Adriana Eramo, Corbo, Vincenzo, Michele Milella   +42 more
core   +1 more source

KRAS mutation analysis by PCR : a comparison of two methods [PDF]

, 2015
Background: KRAS mutation assays are important companion diagnostic tests to guide anti-EGFR antibody treatment of metastatic colorectal cancer. Direct comparison of newer diagnostic methods with existing methods is an important part of validation of ...
Lucas, Katie, Anne Reiman, Reiman, Anne, Louise Bolton, Timms, Judith, Katie Lucas, Ian A Cree, Bolton, Louise, Cree, Ian A., Judith Timms   +9 more
core   +2 more sources